Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020-2021.

Effective partnership and in-country resource mobilization in Sudan for cVDPV2 outbreak response amid multiple emergencies in 2020-2021.

Publication date: Jan 19, 2024

During 2020 and immediately prior to the COVID-19 pandemic, Sudan was experiencing multiple emergencies including violence, seasonal flooding, and vector-borne disease outbreaks. After more than ten years since its last case of wild poliovirus, Sudan declared a circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak on 9 August 2020. cVDPV2 outbreak response data and programme documents of the Federal Ministry of Health and WHO were reviewed. Surveillance data was verified through WHO-recommended procedures for detecting and characterizing polioviruses from stool and sewage samples collected from acute flaccid paralysis (AFP) cases and the environment. This outbreak in Sudan led to a total of 58 confirmed cases of cVDPV2 from 15 of the 18 states. Two nationwide vaccination campaigns were held to increase immunity of children under-five against poliovirus type 2. Funding challenges were overcome by intense additional resource mobilization from in-country sources. The funding gap was bridged from domestic resources (49%) sourced through GPEI partners, and in-country humanitarian funding mechanisms. During an outbreak response and challenge of funding shortfall, mobilizing in-country resources is possible through coordinated approaches, regular communication with partners, disaggregation of needs, and matching in-kind and financial support to fill gaps. A cVDPV2 outbreak requires a fast, resourced, and quality response to stop virus circulation.

Open Access PDF

Concepts Keywords
August cVDPV2 outbreak
Mobilizing Domestic resource mobilization
Polioviruses Emergencies
Sudan Partnership
Poliovirus eradication
Sudan

Semantics

Type Source Name
disease VO effective
disease IDO country
disease MESH emergencies
disease MESH COVID-19 pandemic
disease MESH violence
disease VO Optaflu
disease MESH vector-borne disease
drug DRUGBANK Pentaerythritol tetranitrate
disease VO vaccine
disease MESH acute flaccid paralysis
disease VO vaccination
disease VO Gap
disease IDO quality
pathway REACTOME Reproduction
disease VO immunization
disease VO organization
disease MESH Polio
disease IDO process
disease VO Viruses
disease VO population
disease VO immunized
drug DRUGBANK Trestolone
disease MESH malaria
pathway KEGG Malaria
disease MESH dengue
disease MESH measles
pathway KEGG Measles
disease VO efficient
drug DRUGBANK Etoperidone
disease VO vaccinated
disease VO Oral Poliovirus vaccine
disease VO report
disease MESH infection
disease MESH communicable diseases
drug DRUGBANK Methionine
drug DRUGBANK Coenzyme M
disease VO Poliovirus vaccine
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Spinosad

Original Article

(Visited 1 times, 1 visits today)